Opinion

Video

Review of FDA Approved JAK Inhibitors for Alopecia Areata

Key Takeaways

  • Baricitinib showed significant efficacy in maintaining hair regrowth, with 90% achieving SALT ≤20 and over 70% achieving SALT ≤10 from week 52 to 104.
  • Clinician- and patient-reported outcomes for eyebrow and eyelash regrowth improved between weeks 52 and 104.
SHOW MORE

Video content above is prompted by the following:

a. Baricitinib (n=194, long term study, Senna 2024):

i. Close to 90% of patients maintained SALT ≤20 from week 52 to week 104; SALT ≤10 was achieved by over 70% of patients; clinician- and patient-reported outcomes measurements for eyebrow and eyelash showed increase in response rates between weeks 52 and 104.

ii.TEAEs were reported in 76% of patients taking baricitinib. Most TEAEs were mild to moderate. Most common TEAEs (occurred in ≥5% patients) were COVID-19 infection, upper respiratory tract infection, and headache. One event of major adverse cardiovascular event was reported (<0.1% incidence rate).

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.